Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Tongue hyperpigmentation during hepatitis C treatment

Claude Bachmeyer and Jean-Charles Pellen
CMAJ September 18, 2012 184 (13) 1498; DOI: https://doi.org/10.1503/cmaj.111985
Claude Bachmeyer
From the Department of Internal Medicine, Tenon Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: claude.bachmeyer@tnn.aphp.fr
Jean-Charles Pellen
From the Department of Internal Medicine, Tenon Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

A 47-year-old black woman with chronic hepatitis C (genotype 4) was referred for hyperpigmentation of the tongue. She was a nonsmoker. Eight weeks after treatment with weekly injections of subcutaneous pegylated interferon α-2a and daily oral ribavirin was started for hepatitis C, asymptomatic dark brown patches developed on the dorsum and the apex of her tongue (Figure 1). No other sites were involved. Laboratory examination showed neutropenia with a neutrophil count of 0.88 (normal 1.5–7.0) × 109/L. Investigations including liver enzymes, cortisol and thyroid-stimulating hormone were normal. In the absence of an alternative explanation, an adverse effect of treatment was suspected. The treatment course with interferon and ribavirin was continued until its completion at 48 weeks. During this time, there was a slight increase in hyperpigmentation.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Tongue of a 47-year-old woman with hyperpigmented patches, which developed during treatment with pegylated interferon and ribavirin for chronic hepatitis C.

Hyperpigmentation of the tongue is an uncommon adverse effect of combination therapy with pegylated interferon and ribavirin for hepatitis C, described mainly in dark-skinned patients. In one series, it was observed in 5 of 171 dark-skinned patients versus none in 149 white patients.1 However, instances in white patients have also been reported.2 This adverse effect usually develops within the first few months of treatment, and improves or disappears slowly after the end of therapy. The hyperpigmentation is usually asymptomatic, but a burning sensation may be reported.2 Associated involvement of the gums and oral mucosa, and hyperpigmentation of the skin have been described.1

Histologic examination shows increased amounts of melanin in the basal layer of the epithelium.2 Upregulation of melanocyte-stimulating hormone receptors by interferon-α is suspected, which increases tyrosinase activity in melanocytes and tyrosine, the main precursor of melanin.2,3 The differential diagnosis includes Addison disease, Peutz–Jeghers syndrome, Laugier–Hunziker syndrome, amalgam tattoo, nevi, lichen planus pigmentosus, and adverse reactions to other medications, such as chloroquine and minocycline.

Footnotes

  • Competing interests: Claude Bachmeyer has received consultancy fees from Amgen for treatment of cutaneous adverse drug reactions induced by anti–epidermal growth factor receptor therapy. None declared by Jean-Charles Pellen.

  • This article has been peer reviewed.

References

  1. ↵
    1. Gurguta C,
    2. Kauer C,
    3. Bergholz U,
    4. et al
    . Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C. Am J Gastroenterol 2006;101:197–8.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Farshidi D,
    2. Chiu MW
    . Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C. J Am Acad Dermatol 2010;62:164–5.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Willems M,
    2. Munte K,
    3. Vrolijk JM,
    4. et al
    . Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol 2003;149:390–4.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (13)
CMAJ
Vol. 184, Issue 13
18 Sep 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tongue hyperpigmentation during hepatitis C treatment
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tongue hyperpigmentation during hepatitis C treatment
Claude Bachmeyer, Jean-Charles Pellen
CMAJ Sep 2012, 184 (13) 1498; DOI: 10.1503/cmaj.111985

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Tongue hyperpigmentation during hepatitis C treatment
Claude Bachmeyer, Jean-Charles Pellen
CMAJ Sep 2012, 184 (13) 1498; DOI: 10.1503/cmaj.111985
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • “Superscan” in diffusion-weighted imaging with background body suppression magnetic resonance imaging
  • Using intranasal corticosteroids
  • Langerhans cell histiocytosis in a 5-month-old baby
Show more Practice

Similar Articles

Collections

  • Sections
    • Clinical Images
  • Topics
    • Hepatology
    • Drugs: adverse reactions

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire